ARTHRITIS, PSORIATIC

This study aims to collect long-term safety information for children and teenagers (ages 2 to 18) who are receiving ustekinumab injections for Crohn's disease, ulcerative colitis, or psoriatic arthritis. It is an extension study for participants who benefited from the drug in a p…

This study is testing an investigational drug called JNJ-77242113 (icotrokinra) to see if it can reduce the joint pain, swelling, and skin symptoms of psoriatic arthritis. It involves 552 adults with active psoriatic arthritis who have not tried similar biologic medications befor…

This study is observing over 1,300 people with psoriatic arthritis who are starting one of two types of injectable medications (guselkumab or an IL-17 inhibitor) as part of their regular doctor's care. The main goal is to see how long patients continue taking these medications an…

This study aims to check the long-term safety and effectiveness of an experimental drug called sonelokimab for people with psoriatic arthritis. It is an extension study for about 1,560 participants who have already completed a previous related trial. The main goal is to see how w…

This study is testing whether a new injectable medication called sonelokimab can help control psoriatic arthritis symptoms in adults who haven't tried similar biologic treatments before. Researchers are comparing two dosing schedules of sonelokimab against placebo injections in 9…

This large, late-stage study is testing whether regular injections of a medication called guselkumab can reduce the pain, swelling, and joint damage caused by active psoriatic arthritis. It involved over 1,000 participants who still had symptoms despite standard treatments. The m…

This study is testing an injectable medication called guselkumab for adults with active psoriatic arthritis who did not get enough relief from, or could not tolerate, one prior standard biologic treatment. The main goal is to see if guselkumab is better than a placebo at reducing…